



## A conversation guide for discussing TECVAYLI<sup>®</sup> with your doctor

**TECVAYLI<sup>®</sup> is the first treatment of its kind for multiple myeloma—it's called a bispecific antibody, and it works by binding to both multiple myeloma cells as well as T-cells to help the immune system recognize the multiple myeloma cells and destroy them.**

### **What is TECVAYLI<sup>®</sup> (teclistamab-cqyv)?**

TECVAYLI<sup>®</sup> is a prescription medicine to treat adults with multiple myeloma who:

- have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody to treat their multiple myeloma, **and**
- their cancer has come back or did not respond to prior treatment

TECVAYLI<sup>®</sup> was approved based on patient responses. There are ongoing studies to confirm the clinical benefit of TECVAYLI<sup>®</sup>.

It is not known if TECVAYLI<sup>®</sup> is safe and effective in children.

### **IMPORTANT SAFETY INFORMATION**

#### **What is the most important information I should know about TECVAYLI<sup>®</sup>?**

TECVAYLI<sup>®</sup> may cause side effects that are serious, life-threatening, or lead to death, including Cytokine Release Syndrome (CRS) and neurologic problems.

**Call your healthcare provider right away if you develop any of the signs or symptoms of CRS or neurologic problems listed below at any time during your treatment with TECVAYLI<sup>®</sup>:**

#### **Cytokine Release Syndrome (CRS). Signs and symptoms of CRS may include:**


- |                             |                                |   |
|-----------------------------|--------------------------------|---|
| • fever (100.4°F or higher) | • dizziness or lightheadedness | • confusion or restlessness             |
| • difficulty breathing      | • fast heartbeat               | • headache                              |
| • chills                    | • feeling anxious              | • increased liver enzymes in your blood |

**Please read full Important Safety Information on pages 6-9, and full Prescribing Information, including **Boxed WARNING**, for TECVAYLI<sup>®</sup>.**

How TECVAYLI® works

TECVAYLI® is a kind of medicine called a **bispecific antibody**, which means that it attaches to **2 different cells**

- TECVAYLI® works by helping your immune system locate the multiple myeloma cells in your body
- One side of TECVAYLI® binds to proteins called **CD3**, which are found on your T-cells. The other side binds to proteins called **BCMA**, which are found on multiple myeloma cells (as well as some healthy cells)
- In doing so, TECVAYLI® is able to activate the T-cells in your immune system to destroy the multiple myeloma cells in the rest of your body




Results with TECVAYLI®

TECVAYLI® was studied in **110 heavily pretreated people**:

All patients had previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody:

- At least half of patients received at least **5 prior regimens**
- 78% of patients had **4 prior treatment regimens**



Talk to your doctor for more information about response.

IMPORTANT SAFETY INFORMATION (more)

What is the most important information I should know about TECVAYLI®? (more)

Neurologic problems. Symptoms of neurologic problems with TECVAYLI® include:

- |   |  |  |
|---|--|--|
| • headache  | • muscle spasms                        | • hearing loss                         |
| • jerking movements                                       | • tremor                               | • burning, throbbing, or stabbing pain |
| • rigid muscles   | • double vision                        |  |
| • feeling restless  | • changes in your handwriting          |  |
| • numbness and tingling (feeling like “pins and needles”) | • problems walking                     |  |
| • confusion   | • muscle weakness in your body or face |  |
| • trouble speaking  |  |  |

TECVAYLI® is a ready-to-use treatment and is given:



By a doctor or nurse as a monotherapy, which means it is not administered in combination with other therapies for relapsed or refractory multiple myeloma (RRMM).




As a subcutaneous injection under the skin, usually in your stomach area (abdomen), your thigh, or another area of your body.

TECVAYLI® starts with “step-up” dosing

Step-up dosing is done to reduce the chance of getting cytokine release syndrome (CRS) and/or experiencing neurologic problems by slowly initiating TECVAYLI®, starting with a lower dose. Before each step-up dose and your first treatment dose, you will receive medicines to help reduce your risk and/or lessen the severity of a serious or life-threatening side effect known as CRS. You should be hospitalized for 48 hours after each dose in the step-up dosing schedule. The amount of TECVAYLI® you receive will be based on your body weight.

TECVAYLI® STEP-UP DOSING SCHEDULE



Step-up dose 2 and/or the first treatment dose may be given between 2 to 4 days after the previous step-up dose.

Your healthcare provider will decide the number of days to wait between your doses of TECVAYLI® and how many treatments you will receive. Your schedule may change so your healthcare team can manage any side effects.

Continued treatment will be weekly dosing and may switch to dosing every 2 weeks for certain patients

After step-up dosing, TECVAYLI® is given weekly. If your healthcare provider determines you are responding (a complete response or better) and continue to respond for at least 6 months, you may be able to receive your treatment once every 2 weeks.

TECVAYLI® ONGOING DOSING SCHEDULE



Your healthcare provider will determine if and when your dosing schedule changes based on how you are responding and how long you will receive treatment. After your step-up doses, your healthcare provider will also decide if you need to receive medicines to help reduce your risk of CRS with future doses.

Tell your doctor or healthcare provider about any medications you are currently taking, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

IMPORTANT SAFETY INFORMATION (more)  
What is the most important information I should know about TECVAYLI®? (more)

- Due to the risk of CRS and neurologic symptoms, you should be hospitalized for 48 hours after all doses of TECVAYLI® that are part of the “step-up dosing schedule.” The “step-up dosing schedule” is when you receive the first 2 doses of TECVAYLI®, which are called “step-up doses,” and then you receive the first “treatment dose” of TECVAYLI®. After “step-up dose 1” of TECVAYLI®, the dose of TECVAYLI® is increased.

### What is TECVAYLI® (teclistamab-cqyv)?

TECVAYLI® is a prescription medicine to treat adults with multiple myeloma who:

- have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody to treat their multiple myeloma, **and**
- their cancer has come back or did not respond to prior treatment

TECVAYLI® was approved based on patient responses. There are ongoing studies to confirm the clinical benefit of TECVAYLI®.

It is not known if TECVAYLI® is safe and effective in children.

### IMPORTANT SAFETY INFORMATION

#### What is the most important information I should know about TECVAYLI®?

TECVAYLI® may cause side effects that are serious, life-threatening, or lead to death, including Cytokine Release Syndrome (CRS) and neurologic problems.

**Call your healthcare provider right away if you develop any of the signs or symptoms of CRS or neurologic problems listed below at any time during your treatment with TECVAYLI®:**

**Cytokine Release Syndrome (CRS). Signs and symptoms of CRS may include:**

- |                                |                             |   |
|--------------------------------|-----------------------------|---|
| • fever (100.4°F or higher)    | • fast heartbeat            | • headache                              |
| • difficulty breathing         | • feeling anxious           | • increased liver enzymes in your blood |
| • chills                       | • confusion or restlessness |   |
| • dizziness or lightheadedness |                             |   |

**Neurologic problems. Symptoms of neurologic problems with TECVAYLI® include:**

- |   |                               |  |
|---|-------------------------------|--|
| • headache  | • confusion                   | • problems walking                     |
| • jerking movements                                       | • trouble speaking            | • muscle weakness in your body or face |
| • rigid muscles   | • muscle spasms               | • hearing loss                         |
| • feeling restless  | • tremor                      | • burning, throbbing, or stabbing pain |
| • numbness and tingling (feeling like “pins and needles”) | • double vision               |  |
|   | • changes in your handwriting |  |
- Due to the risk of CRS and neurologic symptoms, you should be hospitalized for 48 hours after all doses of TECVAYLI® that are part of the “step-up dosing schedule.” The “step-up dosing schedule” is when you receive the first 2 doses of TECVAYLI®, which are called “step-up doses,” and then you receive the first “treatment dose” of TECVAYLI®. After “step-up dose 1” of TECVAYLI®, the dose of TECVAYLI® is increased. After “step-up dose 2,” the dose is increased again when you receive the first “treatment dose” of TECVAYLI®.

- “Step-up dose 1” is given on day 1 of treatment. “Step-up dose 2” is usually given on day 4 of treatment. The first “treatment dose” is usually given on day 7 of treatment.
- Your healthcare provider will decide when you will receive “step-up dose 2” and your first “treatment dose.”
  - “Step-up dose 2” may be given between 2 to 4 days after “step-up dose 1,” or up to 7 days after “step-up dose 1” if you have certain side effects with TECVAYLI®.
  - Your first “treatment dose” may be given between 2 to 4 days after “step-up dose 2,” or up to 7 days after “step-up dose 2” if you have certain side effects with TECVAYLI®.
- Your healthcare provider will decide the number of days to wait between your doses of TECVAYLI® as well as how many treatments you will receive.
- If your dose of TECVAYLI® is delayed for any reason, you may need to repeat the “step-up dosing schedule” to receive TECVAYLI®.
- Before each “step-up dose” and your first “treatment dose” of TECVAYLI®, you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicines to help reduce your risk of CRS with future doses.
- Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with TECVAYLI®, as well as other side effects, and treat you as needed.
- **Do not drive or operate heavy or dangerous machinery during and for 48 hours after your TECVAYLI® “step-up dosing schedule” is completed, or at any time during treatment with TECVAYLI® if you develop new neurologic symptoms until the symptoms go away.**

**TECVAYLI® is available only through the TECVAYLI® and TALVEY™ Risk Evaluation and Mitigation Strategy (REMS) due to the risk of CRS and neurologic problems.**

You will receive a Patient Wallet Card from your healthcare provider. **Carry the Patient Wallet Card with you at all times and show it to all of your healthcare providers.** The Patient Wallet Card lists signs and symptoms of CRS and neurologic problems.

**Get medical help right away if you develop any of the signs and symptoms listed on the Patient Wallet Card.** You may need to be treated in a hospital.

- If you have any questions about TECVAYLI®, ask your healthcare provider.
- Your healthcare provider may temporarily stop or completely stop your treatment with TECVAYLI® if you develop CRS, neurologic problems, or any other side effects that are severe.

See **“What are the possible side effects of TECVAYLI®?”** for more information about side effects.

**Before you receive TECVAYLI®, tell your healthcare provider about all of your medical conditions, including if you:**

- have an infection
- are pregnant or plan to become pregnant. TECVAYLI® may harm your unborn baby.



- Your healthcare provider should do a pregnancy test before you start treatment with TECVAYLI<sup>®</sup>.
- You should use effective birth control (contraception) during treatment and for 5 months after your last dose of TECVAYLI<sup>®</sup>.
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with TECVAYLI<sup>®</sup>.
- are breastfeeding or plan to breastfeed. It is not known if TECVAYLI<sup>®</sup> passes into your breast milk. Do not breastfeed during treatment and for 5 months after your last dose of TECVAYLI<sup>®</sup>.

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

#### How will I receive TECVAYLI<sup>®</sup>?

- TECVAYLI<sup>®</sup> will be given to you by your healthcare provider as an injection under your skin (subcutaneous injection), usually in your stomach area (abdomen). Your thigh or another area of your body may be injected.
- **See “What is the most important information I should know about TECVAYLI<sup>®</sup>?” at the beginning of this Important Safety Information for information about how you will receive TECVAYLI<sup>®</sup>.**

If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. It is important for you to be monitored closely for side effects during treatment with TECVAYLI<sup>®</sup>.

#### What are the possible side effects of TECVAYLI<sup>®</sup>?

**TECVAYLI<sup>®</sup> may cause serious side effects, including:**

- See **“What is the most important information I should know about TECVAYLI<sup>®</sup>?”**
- **Liver problems.** TECVAYLI<sup>®</sup> can cause liver problems that may lead to death. Increased bilirubin and liver enzymes in your blood are common with TECVAYLI<sup>®</sup> and can also sometimes be severe. These increases in liver enzymes can happen with or without you also having CRS. Your healthcare provider will monitor you for these problems before you start and during treatment with TECVAYLI<sup>®</sup>. **Tell your healthcare provider if you develop any symptoms of a liver problem including:**
  - tiredness
  - loss of appetite
  - pain in your right upper stomach area (abdomen)
  - dark urine
  - yellowing of your skin or white part of your eyes
- **Infections.** Upper respiratory tract infections and pneumonia are common with TECVAYLI<sup>®</sup>. TECVAYLI<sup>®</sup> can cause bacterial and viral infections that are severe, life-threatening, or that may lead to death.
  - Your healthcare provider will monitor you for signs and symptoms of infection before and during treatment with TECVAYLI<sup>®</sup>.

- Your healthcare provider may prescribe medicines for you to help prevent infections, and treat you as needed if you develop an infection during treatment with TECVAYLI<sup>®</sup>.
- Tell your healthcare provider right away if you get a fever, chills, or any signs or symptoms of an infection.

- **Decreased white blood cell counts.** Decreased white blood cell counts are common with TECVAYLI<sup>®</sup> and can also be severe. Fever sometimes also happens with low white blood cell counts and may be a sign that you have an infection. Your healthcare provider will check your blood cell counts before you start and during treatment with TECVAYLI<sup>®</sup>, and treat you as needed.
- **Allergic reactions and injection site reactions.** TECVAYLI<sup>®</sup> can cause allergic reactions that can affect your whole body (systemic), and also cause injection site reactions.
  - Some people taking TECVAYLI<sup>®</sup> can develop symptoms of an allergic reaction that can affect their whole body and may include fever or a swollen tongue. **Get medical help right away if you develop symptoms of an allergic reaction during treatment with TECVAYLI<sup>®</sup>.**
  - Injection site reactions are common with TECVAYLI<sup>®</sup> and can include: redness, heat, swelling, bruising, bacterial skin infection (cellulitis), discomfort, blood collection under the skin at the injection site (hematoma), and rash. Tell your healthcare provider if you develop any severe injection site reactions.

Your healthcare provider may temporarily or permanently stop TECVAYLI<sup>®</sup> if you have any of the side effects listed above and they are severe.

#### The most common side effects of TECVAYLI<sup>®</sup> include:

- fever
- pain in your joints and muscles, back and chest muscles, and in your arms and legs
- tiredness and weakness
- upper respiratory tract infections and pneumonia. See “Infections” above.
- nausea
- headache
- diarrhea

The most common severe abnormal lab test results with TECVAYLI<sup>®</sup> include: decreased white blood cells, red blood cells, and platelets.

These are not all the possible side effects of TECVAYLI<sup>®</sup>.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**Please read full Prescribing Information, including Boxed WARNING, for TECVAYLI<sup>®</sup>.**

cp-324738v5

## Tips for discussion



You may want to talk about what's important to you at the beginning of your visit, so your doctor knows what is a priority for you.



Come with your questions ready. Make a list of what you want to ask so that if you are pressed for time, you can share the list directly with your doctor. You'll see some sample questions provided on the following pages.



You don't need to face relapsed or refractory multiple myeloma alone. You may want to consider bringing a family member or friend to take notes, or to help you remember or think of new questions.

Use the **Notes pages throughout this brochure** to write down any questions or topics you may want to discuss at your doctor visits. You can also add your own thoughts as you reflect on your journey.

### IMPORTANT SAFETY INFORMATION (more)

**What is the most important information I should know about TECVAYLI®? (more)**

After “step-up dose 2,” the dose is increased again when you receive the first “treatment dose” of TECVAYLI®.

- “Step-up dose 1” is given on day 1 of treatment. “Step-up dose 2” is usually given on day 4 of treatment. The first “treatment dose” is usually given on day 7 of treatment.
- Your healthcare provider will decide when you will receive “step-up dose 2” and your first “treatment dose.”
  - “Step-up dose 2” may be given between 2 to 4 days after “step-up dose 1,” or up to 7 days after “step-up dose 1” if you have certain side effects with TECVAYLI®.
  - Your first “treatment dose” may be given between 2 to 4 days after “step-up dose 2,” or up to 7 days after “step-up dose 2” if you have certain side effects with TECVAYLI®.

## Notes

[illegible]

The following are some questions you may have about **TECVAYLI**<sup>®</sup>. You may have other questions not listed here.

### Considering **TECVAYLI**<sup>®</sup>

- Is **TECVAYLI**<sup>®</sup> right for me at this time?
- Would **TECVAYLI**<sup>®</sup> be a good option for me in the future?
- How are bispecifics different from other multiple myeloma treatment options?
- Does **TECVAYLI**<sup>®</sup> work the same way for everyone?
- Could any of my prior treatments affect how **TECVAYLI**<sup>®</sup> could work for me?
- Could **TECVAYLI**<sup>®</sup> interact with any other treatments I am on?

### Results

- How would I know if **TECVAYLI**<sup>®</sup> is working?
- If I start **TECVAYLI**<sup>®</sup>, how long would I take it?
- What are the potential benefits of **TECVAYLI**<sup>®</sup>?
- What do the different types of responses, such as complete response, stringent complete response, and very good partial response, mean and how does that relate to how I may respond?

### IMPORTANT SAFETY INFORMATION (more)

#### What is the most important information I should know about **TECVAYLI**<sup>®</sup>? (more)

- Your healthcare provider will decide the number of days to wait between your doses of **TECVAYLI**<sup>®</sup> as well as how many treatments you will receive.
- If your dose of **TECVAYLI**<sup>®</sup> is delayed for any reason, you may need to repeat the “step-up dosing schedule” to receive **TECVAYLI**<sup>®</sup>.
- Before each “step-up dose” and your first “treatment dose” of **TECVAYLI**<sup>®</sup>, you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicines to help reduce your risk of CRS with future doses.
- Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with **TECVAYLI**<sup>®</sup>, as well as other side effects, and treat you as needed.

### Side Effects

- What are the possible side effects?
- How would I be monitored for side effects?
- Which side effect signs and symptoms should I tell my care team about?
- What should I do if I think I may be experiencing a side effect?
- What is the most important information I should tell my care team?
- Should I expect the same side effects after step-up dosing is done?
- Would I have to stop taking **TECVAYLI**<sup>®</sup> if I experience side effects?
- Is there anything I could do to reduce the risk of infections?
- Could I still get cytokine release syndrome or have neurologic problems after the step-up dosing is done?

### Starting **TECVAYLI**<sup>®</sup>

- How will I receive **TECVAYLI**<sup>®</sup>?
- Where would I receive my step-up doses?
- What type of time commitment is needed for the step-up dosing period?
- Could I go to my local oncologist for my ongoing doses once all the step-up doses are completed?
- Are there any differences I should know about the step-up dosing schedule and the ongoing dosing schedule?
- Will I be eligible to transition to the biweekly dosing schedule?
- What would happen if I missed a dose?

[illegible]This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.



If you are considering or are currently receiving TECVAYLI<sup>®</sup>, you may have some questions. This guide can help get the conversation started with your doctor.

Visit [TECVAYLI.com](https://www.tecvayli.com) to learn more

Please read full Important Safety Information on pages 6-9, and full Prescribing Information, including Boxed WARNING, for TECVAYLI<sup>®</sup>.